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http:WHAT THIS PAPER ADDS
The 55 mm intervention threshold for abdominal aortic aneurysm (AAA) repair is uniformly accepted; however,
vascular registry data show a high incidence of premature repair (i.e., earlier than indicated by the consensus
guidelines) in clinical practice. To estimate the consequences of the practice of premature repair, a simulation on
the basis of the Medicare data for endovascular aneurysm repair was performed. Conclusions of this simulation
are that although premature AAA repair beneficially influences survival, it comes with considerable costs
(approx. 1 million USD per prevented aneurysm related death) thereby negatively impacting EVAR cost
effectiveness.Background: The reported 54 mm median intervention diameter for endovascular aneurysm repair (EVAR) in the
Vascular Quality Initiative and European data from the Pharmaceutical Aneurysm Stabilisation Trial (PHAST)
implies that in real life the majority of abdominal aortic aneurysm (AAA) repairs occur at diameters smaller than
the consensus intervention threshold of 55 mm. This study explores the potential consequences of this practice.
Methods: The differences between real life AAA repair and consensus based intervention threshold were
explored in reported data from vascular quality initiatives and PHAST. The subsequent consequences of
advancement of endovascular aneurysm repair (EVAR) were estimated using a multistate model based on life
tables for the EVAR Medicare population.
Results: There appears an approximate 5 mm difference in AAA diameter between real life practice and
consensus intervention threshold. Assuming a 2.5 mm annual growth rate, this results in an approximately 2 year
advancement of AAA repair. According to the model used, early repair reduces overall small aneurysm patient
mortality by 2.3%, it results in 21.9% more EVAR procedures, more EVAR related deaths, and 42.3% and 36.8%
more open and endovascular re-interventions, respectively. Costebenefit estimates imply 482 fewer AAA related
deaths, but 140 extra EVAR related deaths for a population of more than 30,000 AAA patients, and a 300 million
USD increase in health costs for the 8 year observation period in the Medicare population.
Conclusions: In the real life situation a large proportion of EVAR procedures appear to occur before reaching the
consensus threshold. Although this reduces mortality, it comes at a cost of approximately 1 million USD per
prevented rupture related death.
 2017 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The United Kingdom Small Aneurysm Trial and Aneurysm
Detection and Management (ADAM) trial reported no sur-
vival benefit for early elective open repair of abdominal
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//dx.doi.org/10.1016/j.ejvs.2017.03.025findings were reported for early elective endovascular
aneurysm repair (EVAR) by the Comparison of surveillance
versus aortic endografting for small aneurysm repair
(CAESAR) and Positive Impact of Endovascular Options for
Treating Aneurysms Early (PIVOTAL) trials.4,5 Consequently,
current guidelines for AAA treatment recommend ultra-
sound follow-up for AAAs smaller than 55 mm for male
patients, after which point surgical repair should be
considered.6 This trade- off is reflected by the respective 59
and 65 mm mean intervention diameters in the Vascular
Study Group of New England (VSGNE) database and the
EVAR 1 trial.7,8
The Consequences of Real Life Practice 29Remarkably, the reported 54 mm median intervention
diameter for EVAR in the Vascular Quality Initiative suggests
that in a real life setting AAA repair occurs earlier than
indicated by prevailing guidelines.9 Similar observations in
the Pharmaceutical Aneurysm Stabilisation Trial (PHAST), a
nationwide study performed in the Netherlands, indicate
that the majority of AAA repairs in patients under surveil-
lance for a small (i.e., <55 mm) AAA occurred at diameters
less than 55 mm.10
Although earlier repair may prevent rupture of small AAA
in some patients, premature repair comes with potential
clinical and financial consequences. To that end, a simula-
tion on basis of a multistate model using real life data from




A multistate model was applied,12 which is used to model
movement of patients among various states in order to
analyse and compare (time to) events. This study is based
on modeling data of 39,966 Medicare patients (22.3% fe-
male) who received elective EVAR between 2001 and
2009.11 The 8 year life table for this Medicare EVAR pop-
ulation was used as a basis for the model.
In this report, the consequences of a 5 mm advancement
of AAA repair for a “real life” setting are simulated. This
5 mm advancement is based on observations of the PHAST
trial10 and on the data from the Vascular Quality Initiative9
and the VSGNE.7 More specifically, data from the PHAST
trial show a 52 (2.7) mm mean (SD) intervention diameter
for the 43 patients undergoing elective AAA repair. This
number is close to the 54 mm median diameter for elective
EVAR in the Vascular Quality Initiative.9 In contrast, data
from the VSGNE indicate a 59 mm mean intervention













0 0.5 39,966 166 0.42 787
0.5 1.0 38,055 138 0.36 635
1.0 1.5 36,835 106 0.29 477
1.5 2.0 34,228 77 0.22 380
2.0 2.5 31,659 84 0.27 342
2.5 3.0 28,884 62 0.21 275
3.0 3.5 26,227 51 0.19 242
3.5 4.0 23,346 49 0.21 198
4.0 4.5 20,580 46 0.22 143
4.5 5.0 17,572 41 0.23 130
5.0 5.5 14,894 40 0.27 106
5.5 6.0 12,096 28 0.23 65
6.0 6.5 9693 32 0.33 48
6.5 7.0 7531 11 0.15 39
7.0 7.5 5562 19 0.34 37
7.5 8.0 3789 12 0.32 20
Total 962 3924
a Number at risk ¼ number at risk previous half year e (number of dConsequently, there appears to be a 5 mm difference in
mean intervention diameters in the VSGNE and Vascular
Quality Initiative7,9 and a 5 mm discrepancy between the
local size readings and the protocolled trial readings in the
PHAST trial,10 suggesting that AAA repair is often performed
at a 5 mm lower diameter in real life settings. Assuming
2.5 mm as the average yearly growth rate for 50 mm AAAs,10
this 5 mm difference will result in an approximately 2 year
earlier repair than indicated by the ultrasound based guide-
lines. On this basis, it was decided to model the conse-
quences of 2 year premature AAA repair for a real life setting.
Primary outcome measures were the number of EVARs,
deaths, and re-interventions. Data for the Medicare
cohort11 hold information on open and endovascular re-
interventions. Open re-interventions were defined as AAA
related secondary open surgical procedures (e.g., open
repair of aneurysm, repair of false aneurysm, removal of
graft, or graft infection). Endovascular re-interventions were
defined as AAA related secondary endovascular procedures
(e.g., stent graft extension, embolisation, aortic or iliac
angioplasty).11
The simulation model was constructed based on the
following assumptions:
(1) the proportion of deaths in the population remains
equal and is not influenced by postponing repair;
(2) the proportion of AAA rupture after EVAR is not
influenced by postponing repair;
(3) the AAA growth rate is 2.5 mm/year and remains stable
over 2 years;10
(4) throughout 8 years of follow-up, interventions related
to the management of the AAA or its complications
will shift 2 years, but the proportion will remain equal;
(5) half of the patients who present with a ruptured AAA
die before emergency repair and will be added to the
number of deaths. The incidence of rupture for AAAs of









1.97 65 0.16 1911 4.78 0 0
1.67 38 0.10 1220 3.21 0 0
1.29 38 0.10 1149 3.12 1458 3.96
1.11 34 0.10 1263 3.69 1306 3.82
1.08 35 0.11 1180 3.73 1595 5.04
0.95 37 0.13 1127 3.90 1530 5.30
0.92 26 0.10 1074 4.10 1807 6.89
0.85 21 0.09 1034 4.43 1732 7.42
0.69 16 0.08 939 4.56 2069 10.05
0.74 23 0.13 808 4.60 1870 10.64
0.71 18 0.12 741 4.98 2057 13.81
0.54 13 0.11 631 5.22 1772 14.65
0.50 7 0.07 540 5.57 1622 16.73
0.52 6 0.08 391 5.19 1578 20.95
0.67 7 0.13 333 5.99 1440 25.89
0.53 8 0.21 207 5.46 e e
392 14,548



























































































































































































































































































































































































































































30 S.M. Tomee et al.(6) 30% of patients undergoing emergency repair will not
survive and will be added to the number of deaths;13
(7) the peri-operative mortality of EVAR is 1.6%.11
Cost analysis was performed on the basis of data for
procedural costs as reported in the EVAR trials (GBP) and
OVER trial (USD).14,15 Both open and endovascular re-
interventions in the Medicare database include a great
variety of clinical procedures with varying degrees of inva-
siveness and technical complexity. Costs were conserva-
tively estimated for open and endovascular re-interventions
at 50% of the costs for respectively open repair and EVAR
published in the OVER and EVAR trials.Analyses
Outcomes in the alternative scenario of the model in which
repair was delayed two years were calculated manually
using the Medicare data as basis.11 The chi-square test was
used to calculate p values.
RESULTS
Life tables containing the events of 8 years for the Medicare
cohort and model cohort are presented in Tables 1e3.
Modeling suggested that 2 year advancement of AAA repair
results in a 2.3% reduction in mortality (Table 4). Yet, this
reduction came at the cost of 21.9% more EVAR procedures
and a 0.96% increase in EVAR related deaths. Moreover,
premature EVAR resulted in a 42.3% and 36.8% increase in
open and endovascular re-interventions, respectively
(Table 5).
A sensitivity analysis was performed for population
mortality and rupture rates (results are presented in
Tables S1-A and S1-B). Based on data from the United
Kingdom Small Aneurysm Trial,1 a 1% annual rupture risk for
AAAs of 40e55 mm was imputed in the model. The influ-
ence of the annual rupture rate on model outcomes were
tested by simulating annual rupture rates of 0.7% and 1.3%.
It showed that an annual rupture rate of 0.7% resulted in
fewer emergency repairs (111) and deaths by AAA rupture
(145), in addition to more EVARs (þ98). In contrast, an
annual rupture rate of 1.3% increased the number of
emergency repairs by 111 and AAA related deaths by 145,
and reduced the number of EVARs by 97.
The first 2 year mortality rate of the small AAA patients in
the Medicare cohort was 13.8%. The influence of different
population specific mortality rates on model outcomes was
estimated by simulating a first 2 year mortality of 10% and
18%. The lower population mortality rate increased the
number of EVARs by 132, EVAR related deaths by 2, and
open and endovascular re-interventions by 1 and 11
respectively. A higher mortality rate reduced the number of
EVAR procedures by 145 and minimally reduced EVAR
related mortality and the number of open and endovascular
re-interventions.
Based on data from the Medicare population, it was
estimated that 2 year advancement of repair resulted in
extra costs of 324.1 million USD for EVAR procedures and







Number of deaths Lost to follow-up
N % N % N % N % N %
0 0.5 31,222 131 0.42 615 1.97 50 0.16 1165 3.73 1574 5.04
0.5 1.0 28,484 103 0.36 476 1.67 28 0.10 1111 3.90 1510 5.30
1.0 1.5 25,863 75 0.29 334 1.29 26 0.10 1060 4.10 1782 6.89
1.5 2.0 23,021 51 0.22 256 1.11 23 0.10 1020 4.43 1708 7.42
2.0 2.5 20,293 55 0.27 219 1.08 22 0.11 925 4.56 2039 10.05
2.5 3.0 17,328 36 0.21 165 0.95 23 0.13 797 4.60 1844 10.64
3.0 3.5 14,687 28 0.19 135 0.92 15 0.10 731 4.98 2028 13.81
3.5 4.0 11,928 25 0.21 101 0.85 11 0.09 623 5.22 1747 14.65
4.0 4.5 9558 21 0.22 66 0.69 8 0.08 532 5.57 1599 16.73
4.5 5.0 7426 17 0.23 55 0.74 10 0.13 385 5.19 1556 20.95
5.0 5.5 5485 15 0.27 39 0.71 7 0.12 329 5.99 1420 25.89
5.5 6.0 3736 9 0.23 20 0.54 4 0.11 204 5.46 e e
Total 565 2480 226 8883
The Consequences of Real Life Practice 3130.3 million USD for secondary re-interventions. These
additional costs of premature EVAR were partially out-
weighed by a reduction in emergency repairs and rupture
related deaths of 0.93% and 1.21%, respectively. Extrapo-
lation of the data from the model, estimates the costs for
one prevented AAA rupture by a 5 mm advancement of
AAA repair at approximately 1 million USD.
Costs per prevented death from rupture were influenced
by different annual rupture rates in the sensitivity analysis,
as annual rupture rates of 0.7% and 1.3% resulted in
approximately 1.7 million and 0.7 million USD per pre-
vented AAA death respectively. Variations in the population
mortality rates minimally influenced the price of one pre-
vented death by AAA rupture, as this remained around 1
million USD.
DISCUSSION
The presented simulation model on the basis of the
Medicare data shows that premature EVAR is associated
with lower mortality but comes with considerable costs. It is
estimated that the costs of one prevented death by rupture
in the Medicare population is around 1 million USD, a price
that may profoundly impact EVAR cost effectiveness. As
large differences in procedural costs exist between
geographical regions the actual consequences of premature
repair for EVAR cost effectiveness may vary per region.
Prevailing guidelines for AAA management recommend
ultrasound follow-up of the aneurysm until 5.5 cm (for
males), at which point consideration for repair needs to beTable 4. Events during 8 years of follow-up in the CT based premature
repair.
Outcomes Medicare cohort and model
Events in 8 years Medicare cohort Model
EVAR repairs 39,966 31,222
Total mortality 14,548 14,884
Open re-interventions 392 226
Endovascular re-interventions 3924 2480
*CI: Confidence interval.made.6 Considering a delay in pre-operative work-up, it is
anticipated that compliance with the guidelines will result
in mean intervention diameters above 55 mm. This is re-
flected by the mean intervention diameters of 65 mm in the
EVAR 1 trial and 59 mm in the Vascular Study Group of New
England (VSGNE) database.8,7
The reported 54 mm median intervention diameter for
elective endovascular repair in the Vascular Quality Initia-
tive shows that in general practice at least half of AAA re-
pairs occurred at diameters below the consensus
intervention threshold.9 Also, in evaluating the PHAST trial
it was observed that a large part of AAA repairs in patients
under surveillance for a small AAA were performed at di-
ameters less than 55 mm.10 As AAA management in this
trial was left to the discretion of the attending physician
and patients’ preferences, this suggests that in real life the
majority of AAA repairs in the participating centres were
premature.
Based on the 2.5 mm of annual growth for aneurysms of
50e55 mm in 286 patients participating in the PHAST study,
the above data imply that in the real life setting AAA repair
occurs around 2 years earlier than would be expected based
on practice guidelines.
The events leading to a premature decision for repair
appear multifactorial, and presumably include patients’ and
doctors’ variables, but also technical factors such as sys-
tematic discrepancy between ultrasound and computed
tomography (CT) based AAA size estimates. Reportedly,
even after correcting for different measuring protocols, CTEVAR Medicare cohort and the simulation model of 2 year delayed









Table 5. Comparison of events and costs after 8 years of follow-up between the Medicare cohort and the 2 years delayed repair simulation
model.
Differences in costs and benefits between Medicare cohort and model
Events in 8 years Differences between Medicare cohort and model Costs per unit
Cohort11 Model £b $c
Mortality due to AAA rupture e 482 e e
Mortality due to EVARa 140f e e e
Emergency repairs e 371 £13 019 $37 068
Elective EVAR repairs 8744 e £13 019 $37 068
Open re-interventionsd 166 e £ 5921 $ 21 485
Endovascular re-interventionse 1444 e £ 6510 $ 18 534
Total costs (in millions) £124.2 £4.83
$354.45 $13.75
a Schermerhorn et al. 1.6% peri-operative EVAR mortality.11
b Brown et al. EVAR 1/2 trials.14
c Lederle et al. OVER trial.15
d Open re-intervention cost is estimated at 50% of elective open repair costs in OVER and EVAR trials.
e Endovascular re-intervention cost is estimated at 50% of elective EVAR costs in OVER and EVAR trials.
f A small difference (6) in cohort mortality exists due to percentages and rounding of life table numbers.
32 S.M. Tomee et al.size estimates are larger than those measured by ultra-
sound.16 Although it has been pointed out that CT is more
accurate in measuring AAA diameter,17 it is important to
note that the 55 mm intervention threshold is based on
ultrasound. As such, CT based size estimates should be
normalised for ultrasound estimates.
Accelerated repair has been advocated as a means of
further reducing AAA related mortality.18 Model outcomes
show a modest effect of early repair on overall mortality but
also that the accompanying costs of early EVAR far exceed
the expected mortality benefit. Consequently, it has been
pointed out that lowering the 55 mm intervention threshold
in AAA treatment cannot be substantiated on basis of the
existing evidence.19
Accelerated AAA repair may negatively impact EVAR cost
effectiveness primarily through a mechanism referred to as
competitive deaths. AAA disease is associated with high
cardiovascular comorbidity and impaired life expectancy
with a 2 year overall mortality rate which can be as high as
20%.11,20 As a consequence, postponing repair will reduce
the need for AAA repair.
There appears to be great variation in AAA treatment be-
tween countries concerning type of intervention and diam-
eter at time of repair. A report by Beck and colleagues21
presenting data of 11 international vascular registries
showed that overall 28% of intact AAAs are repaired at di-
ameters smaller than recommended by guidelines. In
particular, EVAR seems to be associatedwith treating AAAs at
lower diameters (31%).21 These observations are in line with
the data from PHAST10 and the Vascular Quality Initiative.9
Possible explanations for this phenomenon are the lower
procedural risk and impact of EVAR, pressure to meet vol-
ume requirements, and the presumption that earlier repair
is associated with more favourable anatomy, making it more
“difficult” to wait.
Premature decisions for repair will also prolong the in situ
time of a graft by approximately 2 years and thus increase
the likelihood of EVAR related complications and need for
re-interventions.22 Data on the functional life span ofendografts are unavailable. Also, it cannot be stated for
certain that all re-interventions in the Medicare cohort are
due to graft failure, and as such this aspect could not be
fully incorporated in the analysis. Nevertheless, observa-
tions in the Medicare population and EVAR 1 trial identify
long-term stent graft function as a point of concern.11,23
This study has some limitations. First, the consequences
of early AAA repair are based on assumptions. A sensitivity
analysis was performed with various annual rupture rates
(0.7% and 1.3%) and the first 2 year population mortality
rates (10% and 18%) to test for variation in model outcomes
if some model assumptions or parameters were different.
The results showed that EVAR cost effectiveness is mostly
dependent on the effect on AAA related mortality as annual
rupture risks below 1% drastically increase the cost of one
prevented death by AAA rupture to 1.7 million USD. Yet,
financial consequences are obviously influenced by proce-
dural costs which may vary per device and country.
Second, the clinical data are derived from the Medicare
database, which is subject to coding error.11 A third limi-
tation is the extreme variation in reported costs for EVAR
related procedures and re-interventions. The costs for open
repair and EVAR were estimated based on previously re-
ported data.14,15 Costs for re-interventions (i.e., repair of
false aneurysm, stent graft extension, embolisation) are not
available. Those costs were therefore estimated at a con-
servative 50% of the costs of open repair and EVAR. Taking
into account the striking differences in procedure related
costs between the United States and Europe (UK), the costs
for these countries were presented separately. Costs for
other countries may differ from these estimates.
Finally, long-term data from the EVAR 1 trial report AAA
ruptures after elective EVAR.23 This aspect is not included in
the analysis.
In conclusion, although the apparent real life practice of
premature AAA repair moderately reduces AAA related
mortality, it increases the number of EVARs and EVAR
related re-interventions, thereby compromising EVAR cost
effectiveness.




APPENDIX A. SUPPLEMENTARY DATA
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.ejvs.2017.03.025.
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